SSA
TXMD icon

Schonfeld Strategic Advisors’s TherapeuticsMD TXMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,766
Closed -$456K – 1898
2020
Q3 		$456K Buy
+5,766
New +$460K 0.01% 949
2020
Q2 		– Sell
-266
Closed -$14K – 1562
2020
Q1 		$14K Buy
266
+33
+14% +$3.27K ﹤0.01% 1082
2019
Q4 		$28K Sell
233
-317
-58% -$45.6K ﹤0.01% 1238
2019
Q3 		$100K Buy
+550
New +$77.5K ﹤0.01% 948
2017
Q2 		– Sell
-1,373
Closed -$495K – 774
2017
Q1 		$495K Sell
1,373
-569
-29% -$176K 0.05% 369
2016
Q4 		$560K Buy
1,942
+601
+45% +$186K 0.07% 322
2016
Q3 		$457K Buy
+1,341
New +$490K 0.08% 276

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Schonfeld Strategic Advisors's TXMD Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of TherapeuticsMD (TXMD) in Q4 2020, closing a stake of 5,766 shares — an estimated $456K sold.

Schonfeld Strategic Advisors first reported a position in TXMD in Q3 2016 and held it in 7 quarters. The position peaked at $560K in Q4 2016. 159 funds tracked by Wall St. Rank hold TXMD as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining TherapeuticsMD position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 5,766 TherapeuticsMD shares in Q4 2020, an estimated $456K.
  • Schonfeld Strategic Advisors first reported a position in TherapeuticsMD in Q3 2016 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's TherapeuticsMD position peaked at $560K in Q4 2016.
  • 159 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.